Adherence to and outcomes associated with a clostridium difficile guideline at a large teaching institution

Hospital Pharmacy

Volumn 50, Issue 1, 2015, Pages 42-50

  Wieczorkiewicz, Sarah ^a   Zatarski, Raeanna ^a  

^a ADVOCATE LUTHERAN GENERAL HOSPITAL   (United States)

Author keywords

Clostridium difficile infection; guideline adherence; metronidazole; oral vancomycin

Indexed keywords

METRONIDAZOLE; PROTON PUMP INHIBITOR; VANCOMYCIN;

ADULT; AGED; ALGORITHM; ARTICLE; CLINICAL PRACTICE; CLOSTRIDIUM DIFFICILE INFECTION; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; RECURRENCE RISK; TEACHING HOSPITAL;

EID: 84921279039     PISSN: 00185787     EISSN: 19451253     Source Type: Journal    
DOI: 10.1310/hpj5001-042     Document Type: Article

References (16)

1. Tillotson GS, Tillotson J. Clostridium difficile - a moving target. F1000 Med Rep. 2011;3:6.
2. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31:431-455.
3. Schroeder MS. Clostridium difficile-associated diarrhea. Am Fam Physician. 2005;71:921-928.
4. Stevens V, Dumyati G, Brown J, et al. Differential risk of Clostridium difficile infection with proton pump inhibitor use by level of antibiotic exposure [published online ahead of print August 10, 2011]. Pharmacoepidemiol Drug Saf. 5. Elixhauser A, Jhung MA. Clostridium difficile-associated disease in U.S. hospitals, 1993-2005. HCUP Statistical Brief #50. April 2008. Rockville, MD: Agency for Healthcare Research and Quality. www.hcup-us.ahrq.gov/reports/statbriefs/sb50.pdf. Accessed January 4, 2014.
5. Redelings MD, Sorvillo F, Mascola K. Increase in Clostridium difficile-related mortality rates, United States, 1999- 2004. Emerg Infect Dis. 2007;13:1417-1419.
6. Henrich TJ, Krakower D, Britton A, et al. Clinical risk factors for severe Clostridium difficile-associated disease. Emerg Infect Dis. 2009;15:415-422.
7. OBrien JA, Lahue BJ, Caro J, et al. The emerging infectious challenge of Clostridium difficile-associated disease in Massachusetts hospitals: Clinical and economic consequences. Infect Control Hosp Epidemiol. 2007;28:1219-1227.
8. Gerding DN, Johnson S, Peterson LR, et al. Clostridium difficile-associated diarrhea and colitis. Infect Control Hosp Epidemiol. 1995;16:459-477.
9. Hospital Infection Control Practices Advisory Committee (HICPAC). Recommendations for preventing the spread of vancomycin resistance. Infect Control Hosp Epidemiol. 1995;16:105-113.
10. Jung KS, Park JJ, Chon YE, et al. Risk factors for treatment failure and recurrence after metronidazole treatment for Clostridium difficile-associated diarrhea. Gut Liver. 2010;4:332-337.
11. Belmares J, Gerding DN, Parada JP, et al. Outcome of metronidazole therapy for Clostridium difficile disease and correlation with a scoring system. J Infect. 2007;55:495-501.
12. Fernandez A, Anand G, Friedenberg F. Factors associated with failure of metronidazole in Clostridium difficileassociated disease. J Clin Gastroenterol. 2004;38:414-418.
13. Zar FA, Bakkanagari SR, Moorthi KM, et al. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis. 2007;45:302-307.
14. Lou RF, Banaei N. Is repeat PCR needed for diagnosis of Clostridium difficile infection? J Clin Microbiol. 2010;48:3738-3741.
15. Peterson LR, Manson RU, Paule SM, et al. Detection of toxigenic Clostridium difficile in stool samples by real-time polymerase chain reaction for the diagnosis of C. difficileassociated diarrhea. Clin Infect Dis. 2007;45:1152-1160.
16. Hulley SB, Cummings SR, Browner WS, et al. Designing Clinical Research. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2001.